3 completed, 1 recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Recruiting 1 |
Follow retatrutide: new trials by email Literature Review of retatrutide trials Research Report on retatrutide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight Retatrutide (LY3437943), Placebo, Standardized diet and physical activity counseling throughout the study. - Obesity | Phase 2 | Recruiting | Hudson Biotech | 300 | 2026-02-15 | 2026-03-12 |
| A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Retatrutide, Placebo - Overweight or Obesity, CKD | Phase 2 | Completed | Eli Lilly and Company | 146 | 2023-07-20 | 2025-11-25 |
| A Study of LY3437943 in Participants Who Have Obesity or Are Overweight LY3437943, Placebo - Obesity, Overweight | Phase 2 | Completed | Eli Lilly and Company | 338 | 2021-05-20 | 2023-09-13 |
| A Study of LY3437943 in Participants With Type 2 Diabetes LY3437943, Dulaglutide, Placebo - Type 2 Diabetes | Phase 2 | Completed | Eli Lilly and Company | 281 | 2021-05-13 | 2023-07-03 |
Obesity (3) · Diabetes Mellitus, Type 2 (2) · Overweight (2) · Weight Loss (2) · Body Weight (1) · Metabolic Diseases (1) · Overnutrition (1)
Eli Lilly and Company (3) · Hudson Biotech (1)
United States (3) · Puerto Rico (2) · Canada (1) · China (1) · Italy (1) · Spain (1) · United Kingdom (1)
PMID 42608321, PMID 37366315, PMID 37385280, PMID 38858523, PMID 40609566, PMID 41160422, PMID 41201783
2023 (1)